Frequent monitoring for anti-Factor Xa activity (aFXa) and/or activated partial thromboplastin time (aPTT) is required for children receiving heparin therapy to achieve hemostatic balance. However, current heparin tests demand large blood volumes, potentially causing iatrogenic anemia.In this study, we present the preliminary results of a clinical method comparison (12/08/2022 – 6/15/2023) in collaboration with Children’s Healthcare of Atlanta. The study evaluates a rapid (~14-minute), point-of-care digital microfluidic (DMF) platform for aFXa testing. This platform operates directly from low whole blood sample volumes (<50 μL), and the results are compared against an FDA-cleared comparator

 

Read Further:

1. 1. Learn more about Digital Microfluidic Technology
      
   2. Baebies Receives FDA Breakthrough Device Designation for First Point-of-Care Heparin Monitoring Test
      
   3. Baebies Expands Its Vision: Any Test, Anywhere, Everyone™
      
   4. Feasibility of PT, aPTT, and Fibrinogen on a Multifunctional Digital Microfluidic Cartridge
      
   5. Novel Fluorometric Assay for Pediatric Anti-Factor Xa Testing: Minimizing Bilirubin and Hemolysis Interference in Whole Blood